Sprifermin Case Study | Marc Hochberg

Primary Aldosteronism - Dr. Funder (Melbourne)Подробнее

Drug offers osteoarthritis hopeПодробнее

How to manage haematomas | Dr Peter GrossbergПодробнее

JHPS: An interview with Marc PhilipponПодробнее

Panel - Assessment of OA Disease Progression and Long-term Benefit | Session 3Подробнее

Tanezumab and Similar Emerging Therapies – OACS 2020Подробнее

Brain Matters: May 3, 2019Подробнее

Tanezumab and Similar Emerging Therapies – Nancy Lane, MD and Panel | #OACS 2020Подробнее

SPRIL Presents: Dr. Mark McGovernПодробнее

Osteoporosis - Fragility Fracture Management - Session 1 - 15h10 - Sithombo MaqungoПодробнее

Arthritis Research Education Series Ep. 3 - The Puzzle of Hip Pain and Hip Osteoarthritis WebinarПодробнее

Immune Checkpoint Inhibitors and Kidney Disease - Dr. Herrmann (Rochester)Подробнее

M2 - Evolving landscape of PARP inhibitors in mCRPC: combination with anti-androgensПодробнее

TANA Therapeutics has reengineered the industry-standard TAT cell-penetrating peptideПодробнее

New hope for osteoarthritis sufferers found in cancer drug | 9 News AustraliaПодробнее

Panel - Biomarkers in Osteoarthritis Drug Development | Session 2*Подробнее

Simon Hippenmeyer on MADM techniqueПодробнее